Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biopharmaceutical company focused on medicines for genetic diseases, and its news flow reflects both commercial activity and clinical development progress. Company updates frequently highlight Attruby (acoramidis), a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Investors following BBIO news see regular disclosures on Attruby’s commercial performance and new clinical and real-world data from the ATTRibute-CM program and its open-label extension, including analyses of variant ATTR-CM populations and specific genetic subgroups. BridgeBio also reports on late-stage pipeline milestones, such as Phase 3 results for BBP-418 in LGMD2I/R9, topline data and regulatory plans for encaleret in autosomal dominant hypocalcemia type 1, and registrational studies of infigratinib in children with skeletal dysplasias.
News items often include participation in major medical and investor conferences, where BridgeBio presents moderated digital posters, scientific analyses, and corporate updates. Additional releases cover financial and corporate developments, including quarterly business updates, equity inducement grants, royalty monetization transactions related to acoramidis, and proposed offerings of convertible senior notes.
This BBIO news page on Stock Titan aggregates these announcements so readers can review clinical data disclosures, commercial updates, financing transactions, and governance developments in one place. For investors and observers tracking genetic disease drug development and ATTR-CM therapies, the news feed provides a concise view of BridgeBio’s reported progress and key events over time.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved January 23, 2026, to 11 new employees totaling 31,428 restricted stock units.
One-fourth of each award vests on February 16, 2027, then one-twelfth of the remaining shares vests quarterly thereafter, subject to continued employment. Awards were granted under the Amended and Restated 2019 Inducement Equity Plan.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved January 23, 2026 for 12 new employees totaling 34,199 restricted stock units. Awards were granted under the company's Amended and Restated 2019 Inducement Equity Plan.
Vesting: one‑quarter of each employee's RSUs vest on November 16, 2026, then one‑twelfth of the remaining shares vest quarterly thereafter, subject to continued employment. The Plan was originally adopted in November 2019 and amended and restated on February 10, 2023 and December 13, 2023. Grants were made as inducements pursuant to Nasdaq Listing Rule 5635(c)(4).
BridgeBio (Nasdaq: BBIO) priced $550 million of 0.75% convertible senior notes due Feb 1, 2033, with an initial purchaser option for an additional $82.5 million. The company estimates net proceeds of approximately $538.4 million (or ~$619.3 million if the option is exercised) and expects to close on Jan 21, 2026. The notes carry an initial conversion rate of 9.0435 shares per $1,000 (≈$110.58 per share), a ~45% premium to the $76.26 last sale price on Jan 15, 2026. BridgeBio intends to use proceeds to prefund repurchase or repayment of its 2.50% notes due 2027 and for general corporate purposes, and concurrently agreed to repurchase ~1.1 million shares for ~$82.5 million.
BridgeBio (Nasdaq: BBIO) intends to offer $550 million aggregate principal amount of convertible senior notes due 2033, with an initial purchaser option for an additional $82.5 million. The company plans to use net proceeds to repurchase, settle conversion obligations in respect of, or repay a portion of its 2.50% convertible senior notes due 2027 and for general corporate purposes. The notes will bear interest semi-annually, mature on February 1, 2033, and may be convertible into cash, shares or a combination, with conversion and redemption terms determined at pricing. The company also intends to use up to $82.5 million cash to repurchase common shares concurrently with pricing.
BridgeBio (NASDAQ: BBIO) reported preliminary unaudited Q4 2025 Attruby revenue of $146.0M and FY 2025 Attruby revenue of $362.4M, with 6,629 unique patient prescriptions written by 1,632 prescribers as of Dec 31, 2025. The company announced a new TTR amyloid‑depleting antibody program targeting ATTR‑CM expected to enter the clinic in 2027–2028. An interim FORTIFY analysis for BBP‑418 in LGMD2I/R9 showed a 2.6‑point NSAD benefit versus placebo at 12 months and prompted FDA guidance to orient the NDA toward traditional full approval; BridgeBio plans to submit the BBP‑418 NDA in H1 2026. BridgeBio expects an NDA submission for encaleret in ADH1 in H1 2026, will initiate RECLAIM‑HP in summer 2026, and reported LPLV for PROPEL 3 with topline due by end of Q1 2026. Cash and equivalents were approximately $587.5M as of Dec 31, 2025.
BridgeBio (Nasdaq: BBIO) said co-founder and CEO Neil Kumar, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 7:30 am PT. Investors may watch a live webcast via the company’s Investors > Events & Presentations page at http://investor.bridgebio.com. A replay will be available on the company website for 30 days after the presentation.
BridgeBio (Nasdaq: BBIO) will host an investor webinar on Friday, January 9, 2026 at 8:00 am ET featuring Janet Legare, M.D., investigator in the registrational Phase 3 PROPEL 3 study of infigratinib for children with achondroplasia.
Dr. Legare will overview achondroplasia pathophysiology, current unmet need, and the rationale for evaluating infigratinib. Executive members of the skeletal dysplasia program will review the infigratinib clinical program and the ongoing PROPEL 3 study, with topline results expected in Q1 2026.
The live webcast is available via the company’s Events & Presentations page and a replay will be posted for 30 days.
BridgeBio Pharma (Nasdaq: BBIO) announced that on December 18, 2025 its compensation committee approved inducement restricted stock unit grants to 9 new employees totaling 29,472 shares of common stock.
Vesting: one‑quarter of each award vests on November 16, 2026, then one‑twelfth of the remaining shares vests quarterly thereafter, subject to continued employment. Awards were granted under the company’s equity plan adopted November 2019 and amended in February and December 2023, and cited Nasdaq Listing Rule 5635(c)(4) as the inducement basis.
BridgeBio (Nasdaq: BBIO) said members of management will participate in two December investor fireside chats: Piper Sandler Healthcare Conference in New York on Tuesday, December 2 at 10:30 AM ET, and EvercoreISI HealthCONx Conference in Miami on Wednesday, December 3 at 3:00 PM ET.
Live webcasts will be available on the company’s Investors > Events and Presentations page, with replays accessible on the BridgeBio website for 90 days after each event.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved on November 17, 2025 for 12 new employees totaling 34,199 restricted stock units. Awards vest: one-quarter on November 16, 2026, then one-twelfth of the remainder quarterly thereafter, subject to continued employment.
All awards were granted under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan and were designated as inducement grants under Nasdaq Listing Rule 5635(c)(4). The Plan was originally adopted in November 2019 and amended in February and December 2023.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
